Table 1

Baseline characteristics of study participants

All patients (n=149)Patients receiving prophylaxis (n=101)Patients receiving thiopurine monotherapy (n=77)Patients receiving anti-TNF monotherapy (n=11)Patients receiving combination therapy (n=13)No prophylaxis (n=48)
Gender
 Male61 (40.9%)41 (40.6%)33 (42.9%)4 (36.4%)6 (46.2%)20 (41.6%)
 Female88 (59.1%)60 (59.4%)44 (57.1%)7 (63.6%)7 (53.8%)28 (58.4%)
Montreal age
 A1 (below 16 years)30 (20.1%)19 (18.8%)13 (16.9%)2 (18.2%)4 (30.8%)11 (22.9%)
 A2 (17–40 years)91 (61.1%)67 (66.3%)54 (70.1%)7 (63.6%)6 (46.2%) 24 (50.0%)
 A3 (over 40 years)28 (18.8%)15 (14.9%)10 (13%)2 (18.2%)3 (23.1%)13 (27.1%)
Montreal location
 L1 (ileal)27 (18.1%)18 (17.8%)14 (18.2%)2 (18.2%)2 (15.4%)9 (18.8%)
 L2 (colonic)19 (12.8%)8 (7.9%)5 (6.5%)1 (9.1%)2 (15.4%)11 (22.9%)
 L3 (ileocolonic)103 (69.1%)75 (74.3%)58 (75.3%)8 (72.8%)9 (69.2%)28 (58.3%)
Montreal behaviour
 B1 (non-stricturing, non-penetrating)19 (12.8%)12 (11.9%)9 (11.7%)1 (9.1%)2 (15.4%)7 (14.6%)
 B2 (stricturing)90 (60.4%)101 (58.4%)46 (59.7%)5 (45.5%)8 (61.5)31 (64.6%)
 B3 (penetrating)40 (26.8%)30 (29.7%)22 (28.6%)5 (45.5%)3 (23.1%)10 (20.9%)
Previous Crohn's resection53 (35.6%)36 (35.6%)23 (29.9%)6 (54.5%)7 (53.8)17 (35.4%)
Smoking (at time of surgery)46 (30.9%)30 (29.7%)24 (31.2%)3 (27.3%)3 (23.116 (33.3%)
Preoperative treatment
 No immunomodulator53 (34.9%)29 (28.7%)29 (37.7%)01 (7.7%)24 (50.0%)
 Thiopurine90 (60.4%)66 (65.3%)45 (58.4%)10 (90.9%)10 (76.9%)24 (50.0%)
 Methotrexate26 (17.4%)18 (17.8%)6 (7.8%)5 (45.5%)5 (38.5%)8 (16.7%)
 Anti-TNF-α49 (32.9%)34 (33.7%)18 (23.4%)9 (81.8%)7 (53.8%)15 (31.3%)
  • TNF, tumour necrosis factor.